# Kalaris Therapeutics, Inc. (KLRS)

> Source: Nexqual · https://nexqual.com/KLRS · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Kalaris Therapeutics, Inc. (KLRS), nexqual.com/KLRS" · informational, not investment advice.

**Price:** USD 2.19 (+2.82% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 2.13 · day 2.1–2.23 · 52w 2.1–11.88 · market cap $52.1M · NGM

## Key facts
- Analysts: Buy (mean 1.88 on a 1–5 scale) (8 analysts), mean target USD 18.71 (range 7–25).
- Total return with dividends: 1Y -54.3% vs S&P 500 +18.1%; 5Y -99.6% vs S&P 500 +85.1%.

## Analysts
Consensus Buy (mean 1.88 on a 1–5 scale), 8 analysts; mean target USD 18.71 (low 7, high 25).

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | -54.3% | -99.6% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -54.4% | -66.3% |
| Volatility (annualized) | 83.2% | 102.4% |
| Max drawdown | -80.6% (Feb 2026→Oct 2026) | -99.6% (Oct 2021→Oct 2026) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/KLRS · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt